GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of nobody warned me about muscle cramps and I would have liked the warning — 65 comments in the full submission. View in context.
1.1k
c/tirzepatide·submitted 2 months ago by u/kaia_cabrera

nobody warned me about muscle cramps and I would have liked the warning

Questionbranch of 10 comments

nobody warned me about muscle cramps and I would have liked the warning. Change my mind, genuinely — I have no stake in being right about this. Switching from semaglutide, since three people asked in this thread alone. There is no published dose equivalence between the two. The conversion tables that circulate are…

Read the full submission and all 65 comments →

This branch

10 comments, started 2 months ago
u/alcohol_aversion175 points·2 months ago·edited

The four-week interval in the label is a minimum. Nothing about the pharmacology requires you to step on schedule, and the trials stepped on a calendar because trials have to.

replysharereportpermalink
u/aurel_lindqvist257 points·2 months ago

The four-week interval in the label is a minimum.

Saving this one. It is the clearest statement of the stall problem I have read here.

replysharereportpermalink
[removed]169 points·2 months ago

[removed by moderator]

replysharereportpermalink
u/swirl_dont_shakereconstitution106 points·2 months ago

2.5mg is a four-week starting dose, not a maintenance dose. Worth being precise since people search these threads.

replysharereportpermalink
u/kaia_cabreraOP108 points·2 months ago

That percentage is body weight change, not body fat. Different measurement, and the distinction gets lost every time.

replysharereportpermalink
u/mikkel_kimani76 points·2 months ago

pens and vials are the same molecule, the price is the difference

replysharereportpermalink
load more comments (4) →

← back to the whole thread

About c/tirzepatide

Tirzepatide-specific discussion: the dual-agonist pharmacology, the 2.5 → 15mg ladder, the appetite profile people describe as different from semaglutide, and the SURMOUNT/SURPASS trial programme. Comparisons with semaglutide are welcome as long as they are specific about dose equivalence being unknown.

187kmembers
130submissions
Aug 2023created
submissions / month, last year
Sponsored

Sigma-Aldrich Standards

Certified reference materials for peptide identity and purity work.

sigmaaldrich.com
c/tirzepatide rules
  1. "Tirz is better than sema" needs a comparator dose or it is a vibe, not a claim.
  2. Vial-splitting and self-compounding discussion stays in c/reconstitution.
  3. No pen-cracking tutorials. Discussing that people do it is fine; instructions are not.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.